Antiviral Compounds Against Nucleocapsid Protein of Porcine Epidemic Diarrhea Virus
Journal article
Authors/Editors
Strategic Research Themes
No matching items found.
Publication Details
Author list: Deejai N., Roshorm Y.M., Kubera A.
Publisher: Taylor and Francis Group
Publication year: 2017
Journal: Animal Biotechnology (1049-5398)
Volume number: 28
Issue number: 2
Start page: 120
End page: 130
Number of pages: 11
ISSN: 1049-5398
eISSN: 1532-2378
Languages: English-Great Britain (EN-GB)
View in Web of Science | View on publisher site | View citing articles in Web of Science
Abstract
Porcine epidemic diarrhea (PED) is a severe diarrhea disease in swine that is caused by porcine epidemic diarrhea virus (PEDV). Nucleocapsid (N) protein is the RNA-binding protein of PEDV, which plays an important role for virus life cycle. The aim of this research was to screen and characterize the compounds that could inhibit the activity of PEDV N protein. The gene encoding PEDV N protein obtained from PEDV Thai isolate was cloned and expressed in E. coli. Its amino acid sequence was employed to generate the three dimensional structure by homology modeling. There were 1,286 compounds of FDA-approved drug database that could virtually bind to the RNA-binding region of N protein. Three compounds, trichlormethiazide, D-(+) biotin, and glutathione successfully bound to the N protein, in vitro, with the IC50 at 8.754 mg/mL, 0.925 mg/mL, and 2.722 mg/mL. Antiviral activity in PEDV-infected Vero cells demonstrated that the effective concentration of trichlormethiazide, D-(+) biotin, and glutathione in inhibiting PEDV replication were 0.094, 0.094 and 1.5 mg/mL. This study demonstrated a strategy applied for discovery of antiviral agents capable of inhibiting PEDV N protein and PEDV replication. The compounds identified here exhibited a potential use as therapeutic agents for controlling PEDV infection. ฉ 2017 Taylor & Francis.
Keywords
FDA-approved drugs, nucleocapsid protein, porcine epidemic diarrhea virus
Contact Information